NeuroPace CMO granted RSUs and stock options

NeuroPace Inc reported that Chief Medical Officer Martha Morrell received new equity awards.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

NeuroPace Inc reported that Chief Medical Officer Martha Morrell received new equity awards. She acquired 5,460 shares of common stock in the form of restricted stock units, bringing her direct holdings to 52,743 shares of common stock.

She was also granted a stock option for 14,550 shares of common stock at an exercise price of $15.36 per share, expiring on May 14, 2036. The RSUs and options each vest 25% on May 15, 2027, with the remaining portions vesting over subsequent quarterly and monthly installments, respectively.

Insider Trade Summary

Grant/Award: 20,010 shares

Grant/Award 2 txns

Insider Morrell Martha

Role CHIEF MEDICAL OFFICER

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	14,550	$0.00	$0.00
Grant/Award	Common Stock	5,460	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 14,550 contracts (Direct); Common Stock — 52,743 shares (Direct)

Footnotes (2)

F1. Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement. 25% of the RSUs vest on May 15, 2027 and the remaining RSUs vest in twelve (12) equal quarterly installments thereafter.
F2. 25% of the shares subject to the option vest on May 15, 2027. The remaining shares subject to the option vest in thirty six (36) equal consecutive monthly installments thereafter.

Key Figures

RSU grant: 5,460 shares Shares held after grant: 52,743 shares Option grant size: 14,550 shares +3 more

6 metrics

RSU grant 5,460 shares Restricted stock units representing common stock granted on May 15, 2026

Shares held after grant 52,743 shares Total common stock directly held after RSU award

Option grant size 14,550 shares Stock option covering common stock granted on May 15, 2026

Option exercise price $15.36 per share Conversion or exercise price for new stock option

Option expiration May 14, 2036 Expiration date of new stock option grant

Initial vesting date May 15, 2027 25% of RSUs and 25% of option shares vest on this date

Key Terms

restricted stock unit, RSU, Stock Option (Right to Buy), vest, +1 more

5 terms

restricted stock unit financial

"Each share is represented by a restricted stock unit ("RSU")."

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

RSU financial

"Each share is represented by a restricted stock unit ("RSU")."

Restricted stock units (RSUs) are a form of company shares given to employees as part of their compensation, usually with certain restrictions or conditions, such as remaining with the company for a set period. When these restrictions lift, employees receive actual shares that they can sell or hold. For investors, RSUs can impact a company's stock supply and reflect the company's commitment to attracting and retaining talent.

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

vest financial

"25% of the RSUs vest on May 15, 2027 and the remaining RSUs vest in twelve (12) equal quarterly installments thereafter."

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

exercise price financial

"conversion_or_exercise_price: "15.3600""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did NeuroPace (NPCE) CMO Martha Morrell receive?

Martha Morrell received 5,460 restricted stock units and a stock option for 14,550 shares. The option has a $15.36 exercise price and both awards vest over time beginning May 15, 2027.

How many NeuroPace (NPCE) shares does the CMO hold after this Form 4?

After the reported grant, Martha Morrell directly holds 52,743 shares of NeuroPace common stock. This total reflects her position following the 5,460-share restricted stock unit award reported in the filing.

What is the exercise price and term of the new NeuroPace (NPCE) stock option?

The new stock option covers 14,550 shares at an exercise price of $15.36 per share. The option expires on May 14, 2036, giving a long-term window to exercise once vested.

When do Martha Morrell’s new NeuroPace (NPCE) RSUs vest?

Twenty-five percent of the 5,460 RSUs vest on May 15, 2027. The remaining RSUs then vest in twelve equal quarterly installments after that initial vesting date, subject to the award terms.

What is the vesting schedule for the new NeuroPace (NPCE) stock options?

Twenty-five percent of the option shares vest on May 15, 2027. The remaining option shares vest in thirty-six equal consecutive monthly installments thereafter, contingent on the conditions of the grant.

Is this NeuroPace (NPCE) Form 4 a purchase or a compensation grant?

The Form 4 reflects a compensation-related grant, not an open-market purchase. Both the RSUs and stock options were reported with transaction code A, indicating grant or award acquisitions to the Chief Medical Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 05/19/2026 - 04:27 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Morrell Martha

(Last)

(First)

(Middle)

C/O NEUROPACE INC.

455 N. BERNARDO AVENUE

(Street)

MOUNTAIN VIEW

CALIFORNIA

94043

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NeuroPace Inc [ NPCE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CHIEF MEDICAL OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/15/2026		A		5,460⁽¹⁾	A	$0	52,743	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$15.36	05/15/2026		A		14,550		⁽²⁾	05/14/2036	Common Stock	14,550	$0	14,550	D

Explanation of Responses:

1. Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement. 25% of the RSUs vest on May 15, 2027 and the remaining RSUs vest in twelve (12) equal quarterly installments thereafter.

2. 25% of the shares subject to the option vest on May 15, 2027. The remaining shares subject to the option vest in thirty six (36) equal consecutive monthly installments thereafter.

Remarks:

	/s/ Leah Akin, Attorney-in-Fact	05/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR